setmelanotide
Selected indexed studies
- Setmelanotide. (, 2012) [PMID:39083631]
- Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. (Lancet Diabetes Endocrinol, 2022) [PMID:36356613]
- Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. (Lancet Diabetes Endocrinol, 2024) [PMID:38697184]
_Worker-drafted node — pending editorial review._
Connections
setmelanotide is a side effect of
Sources
- Setmelanotide. (2012) pubmed
- Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. (2022) pubmed
- Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. (2024) pubmed
- Setmelanotide: First Approval. (2021) pubmed
- Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity. (2022) pubmed
- Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. (2017) pubmed
- Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. (2020) pubmed
- Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction. (2024) pubmed
- Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity. (2023) pubmed
- PMID:40440436 (2022) pubmed